dependent, Zn++-inhibitable membrane damage steps have occurred. Therefore, HDL or its apoproteins do not act to repair already established transmembrane channels, but might interfere either with insertion of C9 into the lipid bilayer or with polymerization of C9 at C5b-8 sites. This heat-stable inhibitory activity can be demonstrated to modify lysis of erythrocytes in whole serum, i.e., it does not depend upon artificial interruption of the complement membrane attack sequence at any of the above-mentioned stages. Contributions of the target membrane itself to the mechanism of inhibition are suggested by the observations that, in contrast to sheep or normal human E, lysis of guinea pig E or human E from patients with paroxysmal nocturnal hemoglobinuria is inhibited poorly. This is the first description of a naturally occurring plasma inhibitor acting on the terminal, membraneassociated events in complement lysis. Although further study is required to assess the physiologic or immunopathologic significance of this new function of HDL, the HDL apoproteins or their relevant fragments should be useful experimentally as molecular probes of the lytic mechanism.
INTRODUCTION Substantial evidence has accumulated to support the concept that complement (C)'-mediated cytolysis is ' Abbreviations used in this paper: apoA-I and II, apolipoprotein Al and All; apoHDL, a mixture of apoproteins A-I and A-II derived from HDL by chloroform/methanol delipidation; LDL/VLDL, a mixture of low density and very low density lipoproteins; C, complement; HDL, high density lipoproteins; E, erythrocyte; E', human E bearing C5b-9 sites; gp-guinea pig; GVB, 80 mM barbital buffer, pH 7.4, containing 150 mM NaCl and 0.1% gelatin; GVB++, GVB containing 0.5 mM MgCl2 and 0.15 mM CaC12; GVB-E, GVB containing 20 mM EDTA, pH 7.4; hu, human; PBS-E, 10 produced by the interaction of hydrophobic regions of the terminal components, C5-C9, with membrane phospholipids (reviewed in reference 1). Intermediate complexes of the membrane attack mechanism exhibit binding affinity for phospholipids in increasing order from C5b-7 to C5b-8 through C5b-9 (2). Furthermore, under certain conditions, C activation on the surface of erythrocytes (E) (3), liposomes (4), or bacteria (5, 6) can displace phospholipid from the membranes into the aqueous medium, possibly bound to terminal complement complexes (4) . Human serum lipoproteins, presumably by offering alternative hydrophobic sites, are able to compete with membranes for the binding of hydrophobic complement attack complexes generated in the fluid phase. Specifically, it has been shown that the presence of either high density (7) or low density (7, 8) lipoproteins can inhibit the binding of nascent fluid-phase C5b-7 to cell membranes in reactive lysis systems. Another amphiphilic serum protein, the nonlipid-bearing S protein, likewise can bind to C5b-7, and limit its lytic potential for membranes (8, 9) . Thus, hydrophobic proteins such as lipoproteins and S protein may serve a regulatory role in limiting injury to bystander cells when C activation, initiated on neighboring cells or in the fluid phase, produces a shower of fluid-phase C5b6 complexes that could, in turn, form the membranophilic C5b-7, C5b-8, and C5b-9 complexes.
Much less is known about the potential for amphiphilic plasma proteins to act on target cell-bound terminal C components to limit lysis. We have obtained evidence that high density lipoprotein (HDL) and, to a much smaller extent, low density lipoproteins (LDL/ VLDL) from human serum can modulate the lytic effect of the terminal complement components after they are bound to the target cell membrane. This report describes the purification of the major HDL-associated inhibitory activity and its identification as apoproteins A-I and A-II (apoA-I, apoA-II). We also present evidence that HDL or its apoproteins, when added before full insertion of cell bound C5b-9 complexes into the target membrane, can inhibit not only lysis of human (hu) EC5b-8 or sheep EAC1-8 by hu C9, but also lysis of EC5b-9 (human E bearing C5b-9 sites, E°).
METHODS
Cells. Blood was drawn from normal human donors and from a patient (R) with paroxysmal nocturnal hemoglobinuria (PNH) who possessed a homogeneous population (>95%) of type III PNH E (10). E were either stored in Alsever's solution or frozen in glycerol. The lytic behavior of frozen and fresh E was similar. Sheep E were purchased from Cordis Laboratories Inc., Miami, FL, and guinea pig (gp) E from Rockland Laboratories, Gilbertsville, MD.
Complement components and intermediates. Clgp was isolated (11) from fresh-frozen gp serum (Rockland Laboratories). C5 (12), C5b6 (13) , and C9 (14) were isolated from fresh hu serum or fresh-frozen plasma. Human C2, C3, C5, C6, C7, C8, and C9 were purchased from Cordis Laboratories. Sheep EACLgp, 4-7 hu (15) and hu EC5b-7 hu (generated with purified C5b6 and C7 [10] ) were prepared according to published methods. For certain experiments, gp C7 (Cordis Laboratories) was used instead of hu C7, with similar results. For some experiments, EC5b-8 were prepared by incubating hu EC5b-7 with C8 for 20 min at 370C, then washing. For preparation of E°, normal human EC5b-7 were prepared as above. 4 X 107 EC5b-7 in 0.2 ml barbitalbuffered saline containing 0.1% gelatin and 0.02 M EDTA (GVBE), pH 7.4, were shaken with human C8 at 37°C for 15 min. After washing, pelleted EC5b-8 were shaken with human C9 for 1 h at 10°C. After washing once in ice-cold GVB containing 0.5 mM MgCl2 and 0.15 mM CaC12, pH 7.4 (GVB++), E°were suspended to a volume of 1 ml in cold GVB++, and kept on ice until used. Details of individual experiments using E°are given in Results. C8-deficient human serum was kindly supplied by Dr (16) , and the dilution of the inhibitor source producing 50% reduction in Z was determined graphically from a semilog plot of Z vs. inhibitor dilution (inhibitory titer). Fig. 1 demonstrates that similar hemolytic inhibitory titers for a particular preparation (partially purified HDL) are obtained (A) using sheep EAC1-7 bearing C5b-7 sites limited by the C6 input (0.5-1 effective mol/cell), or (B) using sheep EAC1-7 bearing excess C5b-7 sites but with the inhibitor added in the presence of limiting C8 (0.6-2.2 effective mol/cell). This experiment also establishes that the initial number of uninhibited C5b-7 sites per cell is not critical to the inhibitory titer, except possibly at the lowest levels of C6 input (Fig. 1 A) . Most Fig. 2 A, except that three different limiting dilutions of C8 were used. glycol (certified, Fisher Scientific Co., Pittsburgh, PA) and applied to the column equilibrated in the same buffer. The column was eluted with a linear gradient of starting buffer to deionized water, followed by a second linear gradient of water to 95% ethanol. Fractions were dialyzed against 10 mM phosphate buffer, pH 7.4, containing 150 mM NaCl and 10 mM Na3EDTA (PBS-E) and tested for inhibitory activity by the hemolytic assay described above (using sheep EAC1-7), for apoA-I antigens by Ouchterlony analysis, and for C5, C6, C7, C8, and C9 by microtiter adaptation of standard hemolytic assays (15 
RESULTS
During experiments involving reactive lysis, we observed that human EDTA serum was consistently less effective as a C8/C9 source than equivalent or smaller inputs of purified hu C8 and C9 in lysing sheep or hu EC5b-7. This led us to suspect that whole serum possessed an inhibitory activity of a type not previously well characterized. Pilot studies were then conducted, using as a crude inhibitor source hu serum which had been heated at 560C for 3 h to completely destroy C8 and C9 hemolytic activities.2 As shown in Fig. 2 (curve B), addition of 3-h heated serum-EDTA with excess hu C8 and C9 does produce a dose-dependent reduction in lysis of hu EC5b-7 (or sheep EC5b-7, data not shown). Similar results were obtained with heated C8-or C9-deficient hu serum-EDTA (data not shown), indicating that altered C8 or C9 was not the inhibitor. Fresh normal serum-EDTA, admixed with C8 and C9 (added in excess), also induces similar dose-dependent inhibition of lysis (Fig. 2 , curve A). EDTA is not required for this inhibitory effect; nor is interruption of the membrane attack sequence at the C5b-7 or C5b-8 step. The latter was demonstrated in experiments (not shown) in which a purified inhibitor preparation (apoHDL, see below), added to a limiting dilution (1:200-1:400) of fresh human serum, produced dosedependent inhibition of lysis of sheep EA.
Coisolation of plasma inhibitory activity with HDL or its major apoproteins Initial efforts to isolate the protein(s) responsible for this lysis-inhibiting activity of human plasma by ion exchange chromatography or gel filtration were unsuccessful, although starch block electrophoresis localized the activity mainly among the a-globulins. Hydrophobic chromatography on phenyl-Sepharose was more successful. Virtually all inhibitory activity from serum appeared in two distinct peaks on phenylSepharose hydrophobic chromatography (Methods). Both of these peaks contained apoA-I, the major apoprotein of HDL, which is detectable by immunodiffusion in either intact or delipidated HDL. Furthermore, apoA-I was detectable only in the fractions con- (Table I ) and of apoA-II ( Fig. 3 ) than is pool III, but both pools have lower lipid content and higher inhibitory activity on a protein weight basis than does HDL (Table I) . By density gradient ultracentrifugation in CsCl, LDL/VLDL fractions of plasma, which react with anti-f,-lipoprotein but not with anti-apoA-I or antiapoA-II, did contain some inhibitory activity, but with less than half the potency (per microgram protein) of HDL (Table I) . In a representative experiment, -10-20% of the total inhibitory activity recovered from 82 ml of plasma was located in the LDL/VLDL pool. At least 80% of the inhibitory activity from the plasma was recovered in the HDL pool.
Role of apoproteins vs. lipids of HDL in inhibitory activity
Chloroform/methanol delipidation of ultracentrifugally purified HDL yields apoHDL, a mixture of apoA-I and apoA-II in similar ratio to that of intact HDL (Figs. 3 and 4 , tracks a) with small but detectable amounts of residual lipid (Table I) . This material has a higher inhibitory activity on a protein weight basis than does intact HDL, similar to the activity seen with the phenyl-Sepharose pools that have also been partially delipidated by hydrophobic chromatography (Table I) .
The apoproteins (A-I and A-II) of apoHDL were separated by gel filtration on Sephadex G200 in 10 mM Tris buffer, pH 8.6, containing 8 M charcoal-filtered urea and 1 mM EDTA (18) . This procedure yielded pure apoA-I and apoA-II (Fig. 4 ) with no detectable phospholipid or cholesterol (Table I ). The apoA-I contained a small amount of a peptide of smaller apparent molecular weight (Fig. 4, lane b) , which probably reflects degradation of apoA-I, since similar bands have appeared in other delipidated apoA-I-containing preparations upon storage at 00C (but not at -70'C). Nevertheless, despite the somewhat rigorous conditions and prolonged dialysis required for their isolation, the total absence of detectable lipid, and probable selfaggregation (24), both purified apoprotein preparations were quite active in the inhibitory assay (Table  1 ) with activity greater than that of intact HDL, but less than that of unseparated apoHDL.
Purified HDL and the two active phenyl-Sepharose pools were subjected to CsCl density gradient ultracentrifugation (Methods), and fractions were analyzed for density, protein concentration, inhibitory activity and content of apoA-I and A-II (by estimation in SDS-PAGE). For all three inhibitor sources, the lysis-inhibiting activity was highest in high-density fractions (d = 1.21-1.33 mg/ml). These fractions all contained apoA-I, with little or no apoA-II, and are presumably low in lipid. Only a small proportion of the total protein from the HDL preparation appeared in these denser fractions, with the bulk of the apoA-I and apoA- II having densities of 1.14-1.16 mg/ml. Although the lighter HDL fractions did have some inhibitory activity, they were less active on an absolute basis (despite their high protein content) than were the fractions with densities of 1.26-1.31. Phenyl-Sepharose pool I, known to be partially lipid depleted (Table I ) and deficient in apoA-II (Fig. 3) , has the bulk of its apoA-I in this high density range (1.22-1.33), accounting for the high specific inhibitory activity of this pool (Table  I) . Pool Inhibition of formation of EC5b-7. Previous studies by others had shown that HDL (or LDL) can act in the fluid phase to inhibit formation of EC5b-7 from E, C5b6, and C7 (7, 8) , whereas we have found that HDL and particularly its apoproteins can inhibit lysis even after C5b-7 have been bound to the cell membrane. We compared the potency of HDL and delipidated apoHDL for inhibition of the formation of EC5b-7 vs. inhibition of lysis of preformed EC5b-7 by C8 and C9. Human E were incubated with C5b6, C7, and either inhibitor dilutions or buffer (20 min at 370C) and washed. Tubes that had received inhibitor in the first step then received C8, C9 plus buffer, whereas those receiving buffer in the first step received C8, C9, and inhibitor dilutions for the final incubation at 37°C for 60 min. Lysis was measured and 150 (based on protein concentration) of both inhibitor preparations determined as in Fig. 1 . For 50% inhibition of EC5b-7 formation, only 8.3 gg/ml HDL was required, compared with 23.5 gg/ml apoHDL. For 50% inhibition of lysis of preformed EC5b-7 by C8/C9, however, only 3.4 gg/ml apoHDL sufficed, compared with 41.7 Ag/ml of HDL. The ratio of HDL to apoHDL required for inhibition at the C8/C9 step in this experiment is higher than usually observed, but HDL is consistently less active at this stage than is apoHDL, whereas the reverse is true for inhibition of EC5b-7 formation.
Lack of inhibition of preformed C5b-7 sites in the absence of C8 and C9. When hu EC5b-7 or sheep EAC1-7 were incubated with HDL, apoHDL, or buffer (45 min, 37°C), then washed, no effect of either inhibitor on subsequent lysis by C8 and C9 was noted (I50 > 250 gg/ml for both preparations). These same inhibitor preparations exhibited 150 values (in micrograms protein per milliliter) of 32 and 5 for HDL and 5.9 and 0.9 for apoHDL on these hu EC5b-7 and sheep EAC1-7, respectively, when added to the washed cells together with C8 and C9. The greater sensitivity of sheep E intermediates to inhibition, compared with hu E intermediates, has been consistent, but not always in the 6 to 1 ratio shown in this experiment.
Inhibition at the C8 step. No inhibition of lysis was found when apoHDL or HDL were added together with C8 to hu EC5b-7, following by washing and addition of C9. Somewhat variable but minor degrees of inhibition (I50 generally > 250 ,g/ml) were observed when apoHDL or HDL were incubated with pre- Inhibition of cell-bound C5b-9 sites (not fully inserted). The foregoing experiments imply that C9 must be present for the HDL-related inhibitors to be effective. This could reflect (a) an interaction between inhibitor and fluid phase C9; (b) interference with the binding of C9 to C5b-8 sites; or (c) inhibition of events in the lytic process subsequent to C9 binding. The only indirect evidence so far obtained against fluid phase interaction of inhibitor and C9 is that preincubation (25°C, 20 min) of apoHDL or HDL with C9 failed to augment inhibition. As an alternative approach, we prepared E°(EC5b-9, presumably with the C5b-9 sites incompletely inserted), as described in Methods. After adding ice-cold E°to precooled (0°C) inhibitor dilutions or buffer, the mixtures were warmed to 37°C. The design and results of a typical experiment are presented in Table II . HDL, apoHDL and the purified lipid-free apoproteins of HDL, apoA-I and apoA-II, all effectively inhibited lysis of preformed E'. Lower concentrations of apoHDL, apoA-I and apoA-II pro- Step V Step 11 Steps tein sufficed for inhibition of E' lysis than for inhibition of lysis of EC5b-8 by C9 (Table II) [4] [5] [6] , which prevents lysis by osmotic effects but allows insertion of C5b-9 and subsequent membrane damage to occur (26, 27) ; (d) 2 X 1O-4 M ZnSO4 (lines 7-9), which is reported to allow insertion of C5b-9 but block subsequent membrane damage (28) . After 60 min, the cells were sedimented in the cold, supernatants were removed as completely as possible for determination of lysis, and the surviving cells resuspended in GVB++ with or without varying doses of inhibitor (step II). After another 60 min at 37°C, lysis was again determined, and percent lysis calculated on the basis of the number of E* present at the beginning of the experiment.
Inhibition of Complement Lysis by Lipoproteins
The experiment shown in Table III Role of the target cell in susceptibility to HDL-derived inhibitors
In the preceding experiments lipoprotein-derived inhibitors were effective in limiting terminal C-mediated lysis of both normal human E and sheep E. In similar experiments, HDL, apoHDL, and phenyl-Sepharose pool I were added with human C8 and C9 to EC5b-7 formed with gp E or with the most sensitive (type III) E from a patient with PNH (Fig. 5) . The C5b6 and C7 inputs were adjusted to achieve similar uninhibited lysis of all cell types. HDL (panel A) and apoHDL (panel B) had only a minimal effect on terminal lysis of gp EC5b-7 and PNH EC5b-7. In contrast, both preparations were potent inhibitors of terminal lysis of normal human EC5b-7, tested concurrently.
Role of the species source of C8 and C9 in susceptibility to HDL-derived inhibitor
We studied the ability of apoHDL to limit lysis of normal human EC5b-7 by combinations of gp and hu C8 and C9. The inputs of C8 and C9 in each combination were adjusted to provide similar degrees of uninhibited lysis. ability to inhibit C-dependent lysis at a stage after gp C8/gp CC5b-7, C5b-8, and even C5b-9 complexes, have bedr.. \gp C8/gpcome bound to the target membrane. This activity is '., "> \in, thus distinct from the effects of HDL on fluid-phase C5b-7 complexes studied by the groups cited above ', ">z_ L (7, 8) . In their extensive studies on serum inhibitors of reactive lysis, McCleod, Baker, and Gewurz (35) did hu C8/gp C9 A note some inhibition of lysis, by relatively crude serum *No fractions, at a step after C5b-7 binding to target erythrocytes. However, in a subsequent publication from the same laboratory, Lint et al. (7) found that lipoproteins of all classes failed to inhibit the lysis of pre--*\ formed EC5b67 by limiting amounts of C8 and C9, hu C8/hu C9 A whereas the same lipoprotein preparations, particularly HDL, were very effective inhibitors of fluidphase reactive lysis. The latter investigators used gp E to form EC5b67 and we have found that terminal C complexes formed on gp E are far less susceptible o 0.83 1.67 3.33 6.67 13.3 26.7 to the inhibitory effects of HDL and its apoproteins than are similar complexes formed on sheep or human CONCENTRATION OF ApoHDL (Rg/ml) E (Fig. 5) . Thus, an apparent conflict between our data 6 Normal human EC5b-7 were lysed by combi-and those of Lint et al. (7) is explained by the type of of hu and gp C8 and C9 in the presence of serial indicator cell used. Several nonlipid-bearing serum s of apoHDL. The ordinate displays lysis expressed proteins act as inhibitors only on fluid phase C5b-7 or terage number of lytic sites per cell (Z). Uninhibited C5b-9. These include antithrombin III (36), S protein tained by substituting buffer for apoHDL, was made (8) and native C8 (37) Two inhibitors C6 inactivator nately equal for the three cell types by varying the (8) , and nte-C8 (37) . To ginhibitos, rumnctvao f C8 and C9.
(38) and the "C8 analogue" of guinea pig serum (39) , can inhibit cell bound C1-6 or C5b-7, respectively. Since both of these latter inhibitors are markedly heat fective when hu C8 and C9 were used to lyse labile, and the C8 analogue has not been demonstrated s. The I50 for apoHDL was 0.78 ,ug/ml. When in human serum, it is highly unlikely that such factors binations hu C8/gp C9 and gp C8/gp C9 were account for our findings. Thus, our observations appear lyse the cells, the I50 values were 23.8 ttg/ml to reflect a newly recognized modulatory function in- 6 ,gg/ml, respectively. The combination gp C8/ fluencing the terminal events of the C attack mechawhich is known to be ineffective for lysis of nism on a target cell. human EC5b-7 (29) (30) or mouse phenyl-Sepharose coelutes with apoA-I of HDL. Alnphocytes; (b) a possible precursor role of an though individual fractions were not screened for tein of some HDL subclasses in the develop-apoA-II, it is noteworthy that the dominant proteins f secondary (AL) amyloid (32); (c) biologically of the two inhibitory pools from the phenyl-Sepharose Lnt actions of HDL:endotoxin complexes in the columns are apoA-I and apoA-II (Fig. 3) .
hysiology of endotoxemia and endotoxin shock More complete purification of lipoproteins by seits (33, 34) ; and (d) binding of lipoproteins quential CsCl density ultracentrifugation indicated and/or LDL) to fluid phase C5b67 complexes that at least 80% of the inhibitory activity of plasma reactive lysis of bystander cells (7, 8 (Table  I) , and the extracted lipids had no demonstrable inhibitory activity of their own. Furthermore, apoA-I and apoA-II in pure form, free of detectable lipid, were highly (and similarly) active as inhibitors. These observations, together with the observed reduction in inhibitory activity of apoproteins after recombination with extracted lipid, demonstrate that the lysis-inhibiting function of HDL resides in the apoproteins. The theoretical possibility that HDL might act by donating lipids to the target cell membrane is made very unlikely by these findings.
The observation that the ultracentrifugal fractions of HDL with highest inhibitory activity are denser than the bulk of the HDL, and contain apoA-I in excess over apoA-II, suggests that a portion of the HDL-associated apoA-I spontaneously dissociates from the lipoprotein particle, and that this dissociable apoA-I may be the main biologically available inhibitor in plasma. One of the inhibitory peaks from phenyl-Sepharose chromatography of whole serum (pool I) appears to consist mainly of this dissociable apoA-I-rich fraction. Such dissociation of apoA-I from HDL is consistent with the observed exchangeability of apoA-I between lipoprotein classes and subclasses (40) .
Additional studies focused on delineation of the stage in the terminal C sequence at which HDL-related inhibitors act to limit lysis. Preincubation of EC5b-7 with purified HDL or apoHDL or with the active peaks eluted from phenyl-Sepharose, followed by washing, did not inhibit subsequent lysis by C8 and C9; nor could apoHDL block the conversion of C5b-7 to C5b-8 sites by C8. Both HDL and apoHDL were only minimally inhibitory when preincubated with human EC5b-8 or sheep EAC1-8 (followed by washing) before addition of C9. Using I50 values, inhibition was 8-100 times less potent when HDL or apoHDL were removed before addition of C9 compared with the inhibition observed when these inhibitors were added together with C9 to EC5b-8 or EAC1-8. Thus, for maximal effectiveness of the HDL inhibitors, fluid phase or cell-bound (see below) C9 must be present simultaneously.
A key observation, illustrated in Table II , is that HDL and purified apoproteins are capable of inhibiting the lysis of preformed EC5b-9 (E°), in the absence of any fluid-phase source of C9. These cellular intermediates are formed by allowing C9 to bind to EC5b-8 at reduced temperature and washing away the fluid-phase C9. They are stable in the cold (0-10°C) for at least 1 h, but lyse spontaneously upon warming. It has been shown in studies of sheep EACl-9 that the hemolytic function of C9 bound at 0°C is susceptible to inactivation by trypsin before, but not after, the cells have been warmed (27) . Hu (27, 28) with sheep E*. These authors found that the presence of 0.09 M EDTA at 37°C allows insertion of C9 into E4 (as indicated by trypsin resistance), and also allows some additional membrane damage step(s) to proceed (as indicated by a kinetic lag between loss of trypsin sensitivity and the onset of 86Rb release) (27) . Although these cells are osmotically protected from lysis by the EDTA, they are permanently damaged and will lyse after removal of EDTA, even at 0°C (26, 27) . We found that when inhibitor was added to E°at 0°C before insertion of C9, whether EDTA was present or absent, lysis was irreversibly inhibited. If the inhibitor was added after the E* had incubated at 370C in 0.09 M EDTA to allow insertion of C9 (and presumably the subsequent membrane damage steps) to occur, no inhibition was seen (Table  III) . This indicates that the apoproteins are not acting to seal already developed transmembrane channels.
Boyle et al. (28) have presented evidence suggesting that Zn++ ions can reversibly block the postinsertional damage step(s) while still allowing insertion of C9. If these findings using sheep E°can be extrapolated to the human E°used in our system, our observation (Table III) that apoHDL was ineffective when added to E°after preincubation in 2 X 10-4M Zn++ would suggest that these inhibitors can act only before the postinsertional damage step(s) have occurred. If the apoproteins actively interfere with insertion of C9 into the membrane, they could do so (a) by displacing reversibly bound C9 before insertion; (b) by binding to and thus blocking nascent hydrophobic sites on C9 itself (or other nascent hydrophobic portions of the C5b-9 complex); or conceivably (c) by binding to transiently disordered membrane lipids in the vicinity of inserting C5b-9 complexes. Alternatively, if the postinsertional membrane damage step involves polymerization of C9 molecules within the plane of the membrane (42), the apoproteins might interfere with this process. We plan direct binding and membrane extraction studies with radiolabeled C components and apoproteins to resolve some of these issues.
Lipoprotein-derived inhibitors are very inefficient in limiting lysis of gp E and human PNH-III E (Fig.  5) , cell types known to be highly sensitive to reactive lysis with human C (7, 10) . This observation suggests that the cell membrane may play an active or permissive role in the mechanism of inhibition. The HDLderived inhibitors are also much less efficient at limiting lysis when gp C8 and C9, rather than human C8 and C9, are used to lyse the cells (Fig. 6 ). This observed difference in susceptibility to inhibition by human apoHDL lends further support to the hypothesis that gp and hu C9 differ in the mechanism by which they produce cell lysis. The latter hypothesis was suggested by previous studies (29, (44) (45) (46) which indicated that differences in the lytic efficiency of gp and hu C9 are related to events occurring after C9 binding. It is of interest that the primary site of action of lipoproteinderived inhibitors is also at a stage after C9 binding.
The C5b-9 complex is involved in the lysis of bacteria (5, 6) tumor cells (47) , parasites (48, 49) , and in certain forms of lymphocyte-mediated cytotoxicity (50) . Either C9 or the C5b-9 complex has been implicated in several immunopathological processes, including (a) erythrocyte lysis in cold agglutinin disease (51), paroxysmal cold hemoglobinuria (52) , and PNH (10, 53) ; (b) damage to the motor end plate in myasthenia gravis (54) ; (c) damage to basement membrane of skin in patients with systemic lupus erythematosus and discoid lupus (55); (d) damage to glomerular basement membrane in patients with lupus nephritis (56); and (e) experimental damage to alveolar basement membrane of rabbits in vitro (57) . We have shown that the inhibitory activity we are studying is present in whole serum or plasma; that it can protect a human cell (E) from damage by human C5b-9; and that the concentrations of HDL required in our in vitro studies are significantly lower than those present in plasma. Therefore, it is possible that this newly recognized function of HDL and its major apoproteins could play a physiologically significant role in the regulation of both protective and pathologic functions of the membrane attack complex. Furthermore, we believe that the apoproteins or their biologically active fragments will prove to be useful experimentally as molecular probes of the lytic mechanism.
